Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vorinostat + rituximab
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
vorinostat + rituximab is a combination therapy consisting of the histone deacetylase (HDAC) inhibitor vorinostat and the CD20-directed monoclonal antibody rituximab. Vorinostat is a small molecule that inhibits the enzymatic activity of HDACs, leading to the accumulation of acetylated histones and other proteins, which induces cell cycle arrest and apoptosis in cancer cells. Rituximab is a chimeric monoclonal antibody that targets the CD20 antigen on the surface of B-lymphocytes, mediating cell lysis through complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). This combination has been investigated by the City of Hope Medical Center in Phase II clinical trials for the treatment of indolent B-cell non-Hodgkin lymphomas, including follicular, marginal zone, and mantle cell lymphomas, to evaluate if the epigenetic modulation by vorinostat can enhance the efficacy of rituximab-based therapy.
- Brand names
- ZolinzaRituxanMabThera
- Other names
- suberoylanilide hydroxamic acidvorinostat and rituximab
02
Targets
HDAC (HDAC family)CD20 (B-lymphocyte antigen CD20)
Beyond the preview
Go deeper on vorinostat + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vorinostat + rituximab.